about
Computational vaccinology: an important strategy to discover new potential S. mansoni vaccine candidatesSchistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infectionSm10.3, a member of the micro-exon gene 4 (MEG-4) family, induces erythrocyte agglutination in vitro and partially protects vaccinated mice against Schistosoma mansoni infectionSchistosome syntenin partially protects vaccinated mice against Schistosoma mansoni infectionScreening diagnostic candidates for schistosomiasis from tegument proteins of adult Schistosoma japonicum using an immunoproteomic approachSustaining Control of Schistosomiasis Mansoni in Western Côte d'Ivoire: Results from a SCORE Study, One Year after Initial Praziquantel AdministrationGlobal change and human vulnerability to vector-borne diseasesBoudicca, a retrovirus-like long terminal repeat retrotransposon from the genome of the human blood fluke Schistosoma mansoni.Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies.Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda.Schistosoma mansoni Stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection.Comparison of Recombinant Proteins from Schistosoma japonicum for Schistosomiasis Diagnosis.Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge.Schistosoma japonicum UDP-glucose 4-epimerase protein is located on the tegument and induces moderate protection against challenge infection.Evaluation of real-time PCR assay to detect Schistosoma mansoni infections in a low endemic settingA new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasisThe colposcopic atlas of schistosomiasis in the lower female genital tract based on studies in Malawi, Zimbabwe, Madagascar and South Africa.Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.Efficacy of Praziquantel against Schistosoma haematobium in Dulshatalo village, western Ethiopia.Kicking in the Guts: Schistosoma mansoni Digestive Tract Proteins are Potential Candidates for Vaccine DevelopmentA new focus of schistosomiasis mansoni in Hayk town, northeastern Ethiopia.Praziquantel efficacy against Schistosoma mansoni among HIV-1 infected and uninfected adults living in fishing villages along Lake Victoria, Northwest TanzaniaProteomic analysis of schistosoma japonicum schistosomulum proteins that are differentially expressed among hosts differing in their susceptibility to the infection.Evaluation of an IgY-based immunomagnetic enzyme-linked immunosorbent assay system for detection of circulating Schistosoma japonicum antigen in serum samples from patients in ChinaTopical application of DEET for schistosomiasis.Current status and future prospects for a vaccine against schistosomiasis.Comparative Study of the Accuracy of Different Techniques for the Laboratory Diagnosis of Schistosomiasis Mansoni in Areas of Low Endemicity in Barra Mansa City, Rio de Janeiro State, BrazilInvertebrate muscles: muscle specific genes and proteins.Vaccination with enzymatically cleaved GPI-anchored proteins from Schistosoma mansoni induces protection against challenge infection.A cross-sectional study on schistosomiasis and soil-transmitted helminths in Mbita district, western Kenya using different copromicroscopic techniques.Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern EthiopiaImmunization with tegument nucleotidases associated with a subcurative praziquantel treatment reduces worm burden following Schistosoma mansoni challenge.Spatial epidemiology in zoonotic parasitic diseases: insights gained at the 1st International Symposium on Geospatial Health in Lijiang, China, 2007.Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.Evaluation of Lethal Giant Larvae as a Schistosomiasis Vaccine Candidate.Newly established monoclonal antibody diagnostic assays for Schistosoma mansoni direct detection in areas of low endemicityExpression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasisApplication of GIS technology in public health: successes and challenges.Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire.RUMOURS, RIOTS AND THE REJECTION OF MASS DRUG ADMINISTRATION FOR THE TREATMENT OF SCHISTOSOMIASIS IN MOROGORO, TANZANIA.
P2860
Q26852825-B9E76AA3-45D4-4B4D-BD78-584EF1761EAFQ27306926-FD1460D2-5C51-4241-B9C4-C7E40992BB60Q28541196-F074AF1B-5E1C-4CD8-9959-D66E3DAE6567Q28542465-D3282E52-6CC3-4D22-83B8-37A0DF87E6B9Q28543613-EF272A51-4527-473D-91D9-8A62FFFD5C7BQ28552663-956A9BB1-6DCA-4326-81B9-62EA12827FA6Q28776363-B5E28C42-2670-4DEF-95D1-F2F37179C7E0Q33186971-EFA48FCC-578B-45A5-A736-63E26BC1D64EQ33245126-BFD71773-BB6D-43E6-8A50-5878B7519ACAQ33296532-A88115FF-4F76-4EAC-B9F5-C003B82C7BD7Q33531748-304CC3E0-0DD9-45F9-BDC2-7F1D54614853Q33725121-26ADE848-CFEA-4815-A237-4545094AF6C7Q34145933-6D606237-8779-49F0-A555-08B178282C26Q34359443-E56E0432-D092-4D70-B7F7-8C304A980E19Q34409873-C9F44A92-51D3-4DDE-8993-85BD4FDCFE1FQ34500826-3F7D53DE-8D31-4651-A447-D8803EE8C295Q34549601-4D740F0A-FCFD-43C4-8F0D-3F2E37020650Q34939414-A9ED6C75-6713-4AF2-954A-CAAB5C1ECEBFQ35001152-35D20BA4-2AAF-4ADE-8B59-9E16DDE61DFBQ35022286-6AB74542-94D1-4813-9439-77EB135E9005Q35053783-B130703C-B4C9-4F2F-8EC4-6C4FBCFB92A6Q35066116-A146465A-6A35-444D-8D2A-89A8AA2002A8Q35144113-B74E4C5F-6E4C-4728-B6F8-549F60D0637CQ35576035-7DA081CB-18D0-4249-B55E-A7C309EB8833Q35595049-C83C84FE-A1EB-4C97-AF58-20B62FDE99CBQ35791787-05765657-4B54-4325-AB38-231EB82C5777Q36172841-0C8402A0-A1D5-45FE-9ABA-D5AA9B29632BQ36178999-30EB6593-6D65-44FB-8A74-9C3240A8F4F1Q36184801-CA4BDCCD-3A06-4BAA-B944-AE4808E3708BQ36587832-33AB2291-ECF1-4C8B-BC21-B344C72134FCQ36719660-48CE5079-E998-4916-93FA-E10BFD76A757Q36772127-3394A16D-2BAC-4127-B95C-FC2483D289F7Q37145897-B862B79E-805C-46E7-A594-AF090ED3AB7DQ37427225-E54BA12E-5AF0-4241-B215-F04206705ED8Q37430722-B1CC835D-6DCF-42E7-809C-B2691F2FD712Q37539121-4CA80C98-8F7D-4D42-BACB-4249126AA15DQ37694858-33D440AE-C7C1-41A9-8246-A9B7A74C5B43Q38383115-8170FEF3-64F8-4226-A112-70C7EC148BBCQ38452685-7A26962E-6FE3-4133-AF19-BE91A0F095E7Q39055456-CD508D26-C73D-434F-9AFF-38B2893B55A7
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Schistosomiasis: from risk assessment to control.
@ast
Schistosomiasis: from risk assessment to control.
@en
Schistosomiasis: from risk assessment to control.
@nl
type
label
Schistosomiasis: from risk assessment to control.
@ast
Schistosomiasis: from risk assessment to control.
@en
Schistosomiasis: from risk assessment to control.
@nl
prefLabel
Schistosomiasis: from risk assessment to control.
@ast
Schistosomiasis: from risk assessment to control.
@en
Schistosomiasis: from risk assessment to control.
@nl
P1476
Schistosomiasis: from risk assessment to control.
@en
P2093
Nils Robert Bergquist
P304
P356
10.1016/S1471-4922(02)02301-2
P577
2002-07-01T00:00:00Z